Literature DB >> 8657572

Potent antisense oligonucleotides to the human multidrug resistance-1 mRNA are rationally selected by mapping RNA-accessible sites with oligonucleotide libraries.

S P Ho1, D H Britton, B A Stone, D L Behrens, L M Leffet, F W Hobbs, J A Miller, G L Trainor.   

Abstract

Antisense oligonucleotides can vary significantly and unpredictably in their ability to inhibit protein synthesis. Libraries of chimeric oligonucleotides and RNase H were used to cleave and thereby locate sites on human multidrug resistance-1 RNA transcripts that are relatively accessible to oligonucleotide hybridization. In cell culture, antisense sequences designed to target these sites were significantly more active than oligonucleotides selected at random. This methodology should be generally useful for identification of potent antisense sequences. Correlation between oligonucleotide activity in the cell culture assay and in an in vitro RNase H assay supports the proposed role of the enzyme in the mechanism of antisense suppression in the cell.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8657572      PMCID: PMC145867          DOI: 10.1093/nar/24.10.1901

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  20 in total

1.  Stability and covalent modification of P-glycoprotein in multidrug-resistant KB cells.

Authors:  N D Richert; L Aldwin; D Nitecki; M M Gottesman; I Pastan
Journal:  Biochemistry       Date:  1988-10-04       Impact factor: 3.162

2.  Secondary structure in formylmethionine tRNA influences the site-directed cleavage of ribonuclease H using chimeric 2'-O-methyl oligodeoxyribonucleotides.

Authors:  Y Hayase; H Inoue; E Ohtsuka
Journal:  Biochemistry       Date:  1990-09-18       Impact factor: 3.162

3.  Reciprocal correlation between expression of P-glycoprotein and accumulation of rhodamine 123 in human tumors.

Authors:  T Efferth; H Löhrke; M Volm
Journal:  Anticancer Res       Date:  1989 Nov-Dec       Impact factor: 2.480

4.  The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation.

Authors:  K Ueda; D P Clark; C J Chen; I B Roninson; M M Gottesman; I Pastan
Journal:  J Biol Chem       Date:  1987-01-15       Impact factor: 5.157

5.  Defining the inside and outside of a catalytic RNA molecule.

Authors:  J A Latham; T R Cech
Journal:  Science       Date:  1989-07-21       Impact factor: 47.728

Review 6.  Probing the structure of RNAs in solution.

Authors:  C Ehresmann; F Baudin; M Mougel; P Romby; J P Ebel; B Ehresmann
Journal:  Nucleic Acids Res       Date:  1987-11-25       Impact factor: 16.971

Review 7.  An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs.

Authors:  M Kozak
Journal:  Nucleic Acids Res       Date:  1987-10-26       Impact factor: 16.971

8.  Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms.

Authors:  M Y Chiang; H Chan; M A Zounes; S M Freier; W F Lima; C F Bennett
Journal:  J Biol Chem       Date:  1991-09-25       Impact factor: 5.157

9.  Concerning antisense inhibition of the multiple drug resistance gene.

Authors:  J W Jaroszewski; O Kaplan; J L Syi; M Sehested; P J Faustino; J S Cohen
Journal:  Cancer Commun       Date:  1990

10.  Inhibition of viral growth by antisense oligonucleotides directed against the IE110 and the UL30 mRNA of herpes simplex virus type-1.

Authors:  A Peyman; M Helsberg; G Kretzschmar; M Mag; S Grabley; E Uhlmann
Journal:  Biol Chem Hoppe Seyler       Date:  1995-03
View more
  37 in total

1.  Predicting oligonucleotide affinity to nucleic acid targets.

Authors:  D H Mathews; M E Burkard; S M Freier; J R Wyatt; D H Turner
Journal:  RNA       Date:  1999-11       Impact factor: 4.942

2.  Identifying ribozyme-accessible sites using NUH triplet-targeting gapmers.

Authors:  A A Mir; T J Lockett; P Hendry
Journal:  Nucleic Acids Res       Date:  2001-05-01       Impact factor: 16.971

3.  Secondary structure prediction and in vitro accessibility of mRNA as tools in the selection of target sites for ribozymes.

Authors:  M Amarzguioui; G Brede; E Babaie; M Grotli; B Sproat; H Prydz
Journal:  Nucleic Acids Res       Date:  2000-11-01       Impact factor: 16.971

4.  Prioritized selection of oligodeoxyribonucleotide probes for efficient hybridization to RNA transcripts.

Authors:  Kevin J Luebke; Robert P Balog; Harold R Garner
Journal:  Nucleic Acids Res       Date:  2003-01-15       Impact factor: 16.971

5.  Artificial neural network prediction of antisense oligodeoxynucleotide activity.

Authors:  Michael C Giddings; Atul A Shah; Sue Freier; John F Atkins; Raymond F Gesteland; Olga V Matveeva
Journal:  Nucleic Acids Res       Date:  2002-10-01       Impact factor: 16.971

6.  In vitro selection of a purine nucleotide-specific hammerheadlike ribozyme.

Authors:  N K Vaish; P A Heaton; O Fedorova; F Eckstein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

7.  A rapid in vitro method for obtaining RNA accessibility patterns for complementary DNA probes: correlation with an intracellular pattern and known RNA structures.

Authors:  O Matveeva; B Felden; S Audlin; R F Gesteland; J F Atkins
Journal:  Nucleic Acids Res       Date:  1997-12-15       Impact factor: 16.971

8.  Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms.

Authors:  Annemieke Aartsma-Rus; Laura van Vliet; Marscha Hirschi; Anneke A M Janson; Hans Heemskerk; Christa L de Winter; Sjef de Kimpe; Judith C T van Deutekom; Peter A C 't Hoen; Gert-Jan B van Ommen
Journal:  Mol Ther       Date:  2008-09-23       Impact factor: 11.454

9.  Selection of optimal antisense accessible sites of uroplakin II mRNA for bladder urothelium.

Authors:  Liduan Zheng; Qiangsong Tong; Fangmin Chen; Fuqing Zeng; Liang Wang; Jihua Dong
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-06-10

10.  Secondary structure and hybridization accessibility of hepatitis C virus 3'-terminal sequences.

Authors:  Robert M Smith; Cherie M Walton; Catherine H Wu; George Y Wu
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.